Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q2

4544.TEDINET S100S6Z0
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥116.5bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥260.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥134.1bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income−¥1.6bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥17.7bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income−¥1.6bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥22.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥17.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥1.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥20.7bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥15.7bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥284.6bnat 2023-09-30Cons.Assets
Total assets¥297.9bnat 2023-03-31Cons.Assets
Total assets¥287.2bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥134.4bnat 2023-09-30Cons.Liabilities
Total liabilities¥147.9bnat 2023-03-31Cons.Liabilities
Net assets / equity¥150.1bnat 2023-09-30Cons.Net assets
Net assets / equity¥150.0bnat 2023-03-31Cons.Net assets
Net assets / equity¥157.2bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥37.1bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥44.2bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥37.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥37.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥5.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥32.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥15.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥29.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥18.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥7.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-322023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-12.332023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥275.522022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥273.872022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥175.632022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥275.52022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥273.842022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio52.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio50.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio54.7%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥2.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥72.4bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥72.3bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥74m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥6.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥33.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2023-04-01 → 2023-09-30¥564m
—segment totalrevenue2023-04-01 → 2023-09-30¥119.6bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥116.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.2bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥85.1bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥85.0bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥83m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥40.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥35.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥15.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-09-30¥604m
—segment totalrevenue2022-04-01 → 2022-09-30¥139.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥134.1bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥19.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 524
ItemContextValueUnit
Net salesPrior1YTDDuration134081000000JPY
Net salesCurrentYTDDuration116543000000JPY
Cost of salesPrior1YTDDuration83845000000JPY
Cost of salesCurrentYTDDuration84968000000JPY
Gross profitPrior1YTDDuration50236000000JPY
Gross profitCurrentYTDDuration31575000000JPY
Selling general and administrative expensesPrior1YTDDuration32536000000JPY
Selling general and administrative expensesCurrentYTDDuration33144000000JPY
Operating incomePrior1YTDDuration17699000000JPY
Operating incomeCurrentYTDDuration-1569000000JPY
Interest income noiPrior1YTDDuration65000000JPY
Interest income noiCurrentYTDDuration212000000JPY
Dividends income noiPrior1YTDDuration28000000JPY
Dividends income noiCurrentYTDDuration63000000JPY
Foreign exchange gains noiPrior1YTDDuration1028000000JPY
Foreign exchange gains noiCurrentYTDDuration1096000000JPY
Other noiPrior1YTDDuration429000000JPY
Other noiCurrentYTDDuration192000000JPY
Non operating incomePrior1YTDDuration1553000000JPY
Non operating incomeCurrentYTDDuration1564000000JPY
Interest expenses noePrior1YTDDuration187000000JPY
Interest expenses noeCurrentYTDDuration195000000JPY
Equity in losses of affiliates noePrior1YTDDuration1153000000JPY
Equity in losses of affiliates noeCurrentYTDDuration743000000JPY
Loss on investments in capital noePrior1YTDDuration－JPY
Loss on investments in capital noeCurrentYTDDuration406000000JPY
Other noePrior1YTDDuration100000000JPY
Other noeCurrentYTDDuration221000000JPY
Non operating expensesPrior1YTDDuration1441000000JPY
Non operating expensesCurrentYTDDuration1567000000JPY
Ordinary incomePrior1YTDDuration17811000000JPY
Ordinary incomeCurrentYTDDuration-1571000000JPY
Gain on step acquisitions eiPrior1YTDDuration758000000JPY
Gain on step acquisitions eiCurrentYTDDuration－JPY
Gain on transfer of business eiPrior1YTDDuration－JPY
Gain on transfer of business eiCurrentYTDDuration377000000JPY
Other eiPrior1YTDDuration2641000000JPY
Other eiCurrentYTDDuration0JPY
Extraordinary incomePrior1YTDDuration3400000000JPY
Extraordinary incomeCurrentYTDDuration377000000JPY
Loss on valuation of investment securities elPrior1YTDDuration17000000JPY
Loss on valuation of investment securities elCurrentYTDDuration279000000JPY
Loss on valuation of investments in capital elPrior1YTDDuration149000000JPY
Loss on valuation of investments in capital elCurrentYTDDuration－JPY
Loss on valuation of other investments elPrior1YTDDuration197000000JPY
Loss on valuation of other investments elCurrentYTDDuration－JPY
Other elPrior1YTDDuration128000000JPY
Other elCurrentYTDDuration116000000JPY
Extraordinary lossPrior1YTDDuration494000000JPY
Extraordinary lossCurrentYTDDuration396000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass